PIA
MCRB icon

Piedmont Investment Advisors’s Seres Therapeutics MCRB Stock Holding History

Piedmont Investment Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18
Closed -$3K – 1755
2018
Q2 		$3K Buy
+18
New +$2.94K ﹤0.01% 2401

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Piedmont Investment Advisors's MCRB Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Seres Therapeutics (MCRB) in Q3 2018, closing a stake of 18 shares — an estimated $3K sold.

Piedmont Investment Advisors first reported a position in MCRB in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 72 funds tracked by Wall St. Rank hold MCRB as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Seres Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 18 Seres Therapeutics shares in Q3 2018, an estimated $3K.
  • Piedmont Investment Advisors first reported a position in Seres Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Seres Therapeutics position peaked at $3K in Q2 2018.
  • 72 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.